Foundational characteristics of cancer include proliferation, angiogenesis, migration, evasion of apoptosis, and cellular immortality. Find key markers for these cellular processes and antibodies to detect them.
The SUMOplot™ Analysis Program predicts and scores sumoylation sites in your protein. SUMOylation is a post-translational modification involved in various cellular processes, such as nuclear-cytosolic transport, transcriptional regulation, apoptosis, protein stability, response to stress, and progression through the cell cycle.
The Autophagy Receptor Motif Plotter predicts and scores autophagy receptor binding sites in your protein. Identifying proteins connected to this pathway is critical to understanding the role of autophagy in physiological as well as pathological processes such as development, differentiation, neurodegenerative diseases, stress, infection, and cancer.
MAPE Antibody (C-term) Blocking Peptide
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
| Primary Accession | P78395 |
|---|---|
| Clone Names | 80821029 |
| Gene ID | 23532 |
|---|---|
| Other Names | Melanoma antigen preferentially expressed in tumors, Opa-interacting protein 4, OIP-4, Preferentially expressed antigen of melanoma, PRAME, MAPE, OIP4 |
| Target/Specificity | The synthetic peptide sequence used to generate the antibody AP6720b was selected from the C-term region of human MAPE. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay. |
| Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
| Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
| Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
| Name | PRAME {ECO:0000303|PubMed:9047241, ECO:0000312|HGNC:HGNC:9336} |
|---|---|
| Function | Substrate-recognition component of a Cul2-RING (CRL2) E3 ubiquitin-protein ligase complex, which mediates ubiquitination of target proteins, leading to their degradation (PubMed:21822215, PubMed:26138980). The CRL2(PRAME) complex mediates ubiquitination and degradation of truncated MSRB1/SEPX1 selenoproteins produced by failed UGA/Sec decoding (PubMed:26138980). In the nucleus, the CRL2(PRAME) complex is recruited to epigenetically and transcriptionally active promoter regions bound by nuclear transcription factor Y (NFY) and probably plays a role in chromstin regulation (PubMed:21822215). Functions as a transcriptional repressor, inhibiting the signaling of retinoic acid through the retinoic acid receptors RARA, RARB and RARG: prevents retinoic acid-induced cell proliferation arrest, differentiation and apoptosis (PubMed:16179254). |
| Cellular Location | Nucleus. Chromosome. Cytoplasm Golgi apparatus. Cell membrane. Note=Associates with chromatin; specifically enriched at transcriptionally active promoters that are also bound by nuclear transcription factor Y (composed of NFYA, NFYB and NFYC) and at enhancers (PubMed:21822215). Recruited to the Golgi apparatus in response to interferon gamma (IFNG) treatment (PubMed:23460923). |
| Tissue Location | Expressed in testis. Detected in samples of kidney, brain and skin. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
MAPE is an antigen that is predominantly expressed in human melanomas and that is recognized by cytolytic T lymphocytes. It is not expressed in normal tissues, except testis. This expression pattern is similar to that of other CT antigens, such as MAGE, BAGE and GAGE. However, unlike these other CT antigens, its gene is also expressed in acute leukemias.
References
Rezvani,K., Blood 113 (10), 2245-2255 (2009)Qin,Y., Leuk. Res. 33 (3), 384-390 (2009)Neumann,E., Cancer Res. 58 (18), 4090-4095 (1998)
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.
Ordering Information
Other Products
Shipping Information
